Hinova Pharmaceuticals (SH:688302) 智通财经网·2025-11-04 08:36Core Viewpoint - Haichuang Pharmaceutical (688302.SH) has completed the enrollment of the first batch of participants in the Phase II clinical trial for HP515, a drug aimed at treating Metabolic Associated Steatotic Hepatitis (MASH), with no similar targeted products approved in China as of the announcement date [1] Group 1: Product Development - HP515 is an orally administered, highly selective THR-β (thyroid hormone receptor beta subtype) agonist developed by the company [1] - The drug works by activating downstream gene transcription through THR-β, enhancing lipid metabolism in liver cells, improving liver fat metabolism, and reducing lipotoxicity to alleviate MASH [1] Group 2: Regulatory Approvals - HP515 received approval from the National Medical Products Administration of China for MASH treatment in August 2024 [1] - The drug also obtained approval from the U.S. Food and Drug Administration for MASH treatment in September 2024 [1]